Bristol-Myers Squibb Co Stock Price, News & Analysis

Bristol Myers Squibb (NYSE: BMY) has announced its participation in the Goldman Sachs 46th Annual Global Healthcare Conference scheduled for June 11, 2025. The company will engage in a fireside chat starting at 10:00 a.m. ET. Both investors and the general public can access the session through the company's investor relations website at http://investor.bms.com. An archived recording of the session will be made available after its conclusion.

Bristol Myers Squibb (NYSE: BMY) has received European Commission approval for Opdivo SC, a new subcutaneous formulation of its PD-1 inhibitor nivolumab, across multiple solid tumor indications. This marks Opdivo as the first and only PD-1 inhibitor approved for subcutaneous use in the EU. The approval is based on the Phase 3 CheckMate -67T trial, which demonstrated noninferiority in pharmacokinetics and consistent efficacy compared to the intravenous formulation. The new formulation reduces administration time to just 3-5 minutes, compared to traditional IV infusion. The approval covers use as monotherapy, maintenance therapy following IV nivolumab plus Yervoy combination, or in combination with chemotherapy or cabozantinib. The safety profile remained consistent with the IV formulation, with serious adverse reactions occurring in 28% of patients.

Bristol Myers Squibb (NYSE: BMY) will present data from over 80 studies across 20+ cancer types at the 2025 ASCO Annual Meeting (May 30-June 3, Chicago). Key highlights include: • Head & Neck Cancer: Phase 3 NIVOPOSTOP study results of adjuvant nivolumab with radio-chemotherapy for high-risk HNSCC • Lung Cancer: 5-year survival analysis from CheckMate-816 studying Opdivo with chemotherapy for NSCLC • Esophageal Cancer: 5-year OS results from CheckMate-577 evaluating adjuvant Opdivo • Blood Disorders: First OS results from COMMANDS study comparing Reblozyl vs. epoetin alfa in MDS patients • Pipeline Updates: Data on BMS-986504 for MTAP-deleted tumors, KRAZATI for KRAS-mutated NSCLC, and iza-bren for lung cancers • Cell Therapy: Analysis of Breyanzi treatment in over 1,500 patients and arlo-cel data in multiple myeloma

Bristol Myers Squibb (NYSE: BMY) has announced its participation in the Bernstein 41st Annual Strategic Decisions Conference scheduled for Wednesday, May 28, 2025. The company will engage in a fireside chat starting at 3:30 p.m. ET. Both investors and the general public can access the session through the company's investor relations website at investor.bms.com. An archived version of the session will be made available after its conclusion.

Bristol Myers Squibb (BMY) has received European Commission approval for a perioperative regimen of Opdivo with chemotherapy followed by adjuvant Opdivo for treating resectable non-small cell lung cancer (NSCLC) with PD-L1 expression ≥1%. The approval is based on the CheckMate-77T trial, which demonstrated a 42% reduction in the risk of disease recurrence, progression, or death compared to chemotherapy and placebo. After 24 months, 65% of patients in the Opdivo arm showed event-free survival versus 44% in the control arm. The trial also showed improvements in pathologic complete response and major pathologic response, with a safety profile consistent with previous studies. This approval makes Opdivo the only PD-(L)1 inhibitor approved for both perioperative and neoadjuvant-only treatment of resectable NSCLC in the EU.

Bristol Myers Squibb (NYSE: BMY) has appointed Cari Gallman as Executive Vice President, General Counsel and Chief Policy Officer, effective immediately. Gallman, who has been with BMY for 10 years and most recently served as Executive Vice President of Corporate Affairs, succeeds Sandra Leung, who is retiring after 33 years with the company.

In her new role, Gallman will lead the law department, overseeing intellectual property, commercial and regulatory law, litigation, securities and corporate governance, transactions, corporate security, compliance and ethics, as well as global and U.S. policy and government affairs. She brings extensive experience in pharmaceutical law and compliance, along with expertise in legal, policy, and communications.

Bristol Myers Squibb (BMY) reported Q1 2025 financial results with total revenues of $11.2 billion, declining 6% year-over-year. The company's Growth Portfolio showed strong performance with revenues of $5.6 billion, increasing 16% (+18% Ex-FX), driven by Opdivo, Breyanzi, Reblozyl and Camzyos.

Key financial metrics include GAAP EPS of $1.20 and non-GAAP EPS of $1.80. The Legacy Portfolio revenues declined 20% to $5.6 billion due to generic impact on key products and U.S. Medicare Part D redesign effects.

BMY has raised its 2025 guidance, with revenue now expected between $45.8-$46.8 billion (previously ~$45.5 billion) and increased non-GAAP EPS guidance to $6.70-$7.00. The improved outlook reflects strong Growth Portfolio performance and better-than-expected Legacy Portfolio sales in Q1 2025.

Bristol Myers Squibb (NYSE: BMY) announced topline results from the Phase 3 ARISE trial evaluating Cobenfy as an adjunctive treatment to atypical antipsychotics in adults with schizophrenia. The trial did not achieve statistical significance in its primary endpoint, showing only a 2.0-point reduction in the PANSS total score compared to placebo (P = 0.11).

Key findings include:

• Cobenfy demonstrated a -14.3 point change in PANSS Total Score vs -12.2 for placebo
• Post-hoc analysis revealed better responses in non-risperidone treated patients (-3.4 point difference, P = 0.03)
• Safety profile remained consistent with previous monotherapy trials

Despite not meeting the primary endpoint, the company plans to complete further analysis and discuss potential next steps with regulators. The clinical development program continues across multiple neuropsychiatric conditions, including Alzheimer's disease, autism spectrum disorder, and bipolar disorder.

Bristol Myers Squibb (NYSE: BMY) announced that the FDA has updated the U.S. Prescribing Information for CAMZYOS®, their cardiac myosin inhibitor for treating obstructive hypertrophic cardiomyopathy (oHCM). The key updates include:

• Reduced echo monitoring frequency from every 12 weeks to every 6 months for eligible maintenance phase patients
• Removal of contraindications for moderate CYP2C19 inhibitors and strong CYP3A4 inhibitors
• Expanded patient eligibility with revised dosing and monitoring guidelines

These updates are supported by long-term clinical and real-world data from over 15,000 U.S. patients, including REMS Program analyses and three single-center studies showing safety through 3.5 years. CAMZYOS remains subject to a Boxed WARNING for heart failure risk and is only available through a restricted REMS program.